30 Participants NeededMy employer runs this trial

Sarecycline vs Doxycycline for Acne

NA
Overseen ByNasima Afzal Chief Operating Officer
Age: Any Age
Sex: Any
Trial Phase: Phase 4
Sponsor: Integrative Skin Science and Research
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is being done to help better understand how the gut and skin bacteria of the body change when people with acne are treated with Sarecycline or Doxycycline. The bacteria in the gut and on the skin will be studied to see how each treatment may affect them and whether they change the profile of the bacteria that is present.

Who Is on the Research Team?

RS

Raja Sivamani, MD

Principal Investigator

Integrative Skin Science and Research

Are You a Good Fit for This Trial?

Inclusion Criteria

I have at least 10 inflamed acne spots and up to 100 non-inflamed acne spots.
I have two or fewer nodules on my face.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2 weeks

Treatment

Participants receive either Sarecycline or Doxycycline to assess changes in gut and skin microbiome

4 weeks
Weekly visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Doxycycline
  • Sarecycline

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Sarecycline GroupExperimental Treatment1 Intervention
Group II: Doxycycline GroupExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Integrative Skin Science and Research

Lead Sponsor

Trials
33
Recruited
2,000+

Almirall, S.A.

Industry Sponsor

Trials
63
Recruited
19,200+

Carlos Gallardo Piqué

Almirall, S.A.

Chief Executive Officer since 2023

MS in Industrial Engineering from Universitat Politècnica de Catalunya, MBA from Stanford Graduate School of Business

Mercedes Diz

Almirall, S.A.

Chief Medical Officer since 2023

PhD in Biochemistry